Printer Friendly

China Biopharma, Inc. Retains The Global Consulting Group As Investor Relations Counsel.

PRINCETON, N.J. -- China Biopharma, Inc. (OTCBB: TEDG) has retained The Global Consulting Group, a strategic consulting firm headquartered in New York, to provide investor relations and financial communications counsel.

"We are delighted to have The Global Consulting Group represent China Biopharma," said Mr. Peter Wang, the Chairman and CEO of China Biopharma, Inc.. "Their strong investor relations track record in the healthcare sector, its keen understanding of the Chinese marketplace and its strong ability to enhance shareholder value for clients were the key reasons we selected them to assist us in our investor relations efforts. We believe that The Global Consulting Group's effective communications programs and impressive reputation of developing long-term relationships with the investment community will enable China Biopharma, to generate investor awareness and visibility."

"We are very excited to work with China Biopharma, Inc.," stated Dr. Richard Wolff, CEO of The Global Consulting Group. "China Biopharma, Inc. is in fast growing biopharmaceutical area in China. With the large population base and growing senior citizen group in China, there are huge potentials for vaccines and biopharmaceutical products. We are confident that our bilingual China team will successfully assist in the strategic planning and disciplined execution of China Biopharma, Inc.'s ongoing communications effort."

About China Biopharma, Inc.

China Biopharma is a fast growing developer, producer and distributor of biopharmaceutical products in China. Through its wholly owned subsidiary, China Biopharma Limited, the Company owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd. The Company's current products consist of human vaccines against influenza, epidemic hemorrhagic fever (HFV), and Japanese Encephalitis (JEV). Through its investment and ownership of local Chinese biopharmaceutical companies, the Company plans to build a leading biopharmaceutical company in China by leveraging its manufacturing and marketing capabilities and introducing advanced technologies, best products, and an experienced management team. With a fast growing market, newly completed production facilities, and several other new vaccines in the pipeline, the Company expects to see steady business growth in the near future. For more information, visit its website at

About The Global Consulting Group

The Global Consulting Group, a wholly-owned subsidiary of Huntsworth PLC, is headquartered in New York, with offices in Chicago, Los Angeles, Sacramento, London, Edinburgh, Madrid, Brussels, Shanghai, Hong Kong, Sao Paolo and Tel Aviv. The firm's 120 employees strategically spread out over 3 continents, services over 200 global clients in 12 languages. The firm focuses on providing consulting services to privately-held and publicly-traded corporate clients in three areas: investor relations, corporate communications and public affairs. For more information, please visit


The statements made in this press release that are not historical fact are "forward-looking statements" which are based upon current expectations that include a number of risks and uncertainties. Additional factors that could potentially affect the Company's financial results may be found on the Company's filings with the Securities and Exchange Commission (
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 15, 2006
Previous Article:Cycle Country Announces Third Quarter Results; Three of Four Operating Divisions Increase by Nearly Double Digits.
Next Article:IT Security World Brings Together Six Events Under One Roof; Summits Focus on Security Related Issues and Topics Within Top Sectors.

Related Articles
Advance Nanotech's Michael Helmus, Ph.D. to Co-Chair Session at ASM International Materials and Medical Devices Conference.
Bodisen Biotech Retains The Piacente Group as U.S. Investor Relations Counsel.
China Natural Gas, Inc. Retains The Piacente Group as U.S. Investor Relations Counsel.
Meade Instruments Retains The Piacente Group as Investor Relations Counsel.
China BioPharma Issues Profile on
CSMG Technologies Retains ROI Group Associates as Investor Relations Counsel.
US Energy Initiatives Retains Investor Relations Firm Core Consulting Group.
China Health Holding Retains Investor Relations International for Strategic IR Effort.
China Biopharma CEO to Participate as Panelist at Biotech 2006.
China Ivy School, Inc. Hires The Investor Relations Group of New York.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters